{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:32:51Z","timestamp":1792740771530,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>The total functioning capacity (TFC) assessment has been integral to Huntington's disease (HD) research and clinical trials, measuring disease stage and progression. This study investigates the natural progression of function in HD, focusing on changes in TFC scores related to age and CAG-repeat length, and evaluates TFC's strengths and weaknesses in longitudinal studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using Enroll-HD platform's clinical dataset version 5, including Registry-3, we analysed data from 21,079 participants, with 16,083 having an expanded CAG repeat. Our final analysis encompassed 15,527 patients and 52,457 visits, with TFC scores ranging from 0 to 13.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Alluvial charts show that most individuals maintain maximum functional capacity over time. 3505 individuals experienced change in TFC scores, over the subsequent 4 years, 2224 (64.1%) experienced declining TFC scores, while 661 (18.6%) showed improvement within a year. The remaining 17.3% exhibited stable TFC scores. Age-related changes followed a specific sequence: occupation, household chores\/finances, daily living, and care. Longer CAG-repeat lengths were linked to earlier functional decline, with some geographic regions showing earlier losses in specific domains. Reduced penetrance CAG-repeat groups exhibited different trajectories from full penetrance HD participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>When we focus on those who experienced a change in TFC score, the number of HD patients with regained functional capacity is substantial, even considering interrater variability, which may influence outcome assessments in clinical trials. The TFC effectively reflects changes in functional domains as intended. Analysis of the reduced penetrance group suggests potential selection biases in seeking medical attention earlier and for reasons unrelated to HD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-024-12771-w","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T08:28:50Z","timestamp":1736929730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Total functioning capacity scale in Huntington's disease: natural course over time"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5532-5553","authenticated-orcid":false,"given":"K. F.","family":"van der Zwaan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1160-0920","authenticated-orcid":false,"given":"S.","family":"Feleus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-7580","authenticated-orcid":false,"given":"O. M.","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5591-1133","authenticated-orcid":false,"given":"R. A. C.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-2468","authenticated-orcid":false,"given":"S. T.","family":"de Bot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"4","key":"12771_CR1","doi-asserted-by":"publisher","first-page":"a033118","DOI":"10.1101\/cshperspect.a033118","volume":"10","author":"MG Erkkinen","year":"2018","unstructured":"Erkkinen MG, Kim MO, Geschwind MD (2018) Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol 10(4):a033118. https:\/\/doi.org\/10.1101\/cshperspect.a033118","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"12771_CR2","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","volume":"11","author":"JS Paulsen","year":"2011","unstructured":"Paulsen JS (2011) Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep 11(5):474\u2013483","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"12771_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"M Macdonald","year":"1993","unstructured":"Macdonald M (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72(6):971\u2013983","journal-title":"Cell"},{"key":"12771_CR4","volume-title":"Practical neurology","author":"J Biller","year":"2012","unstructured":"Biller J (2012) Practical neurology. Lippincott Williams & Wilkins"},{"issue":"1","key":"12771_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.29.1.1","volume":"29","author":"I Shoulson","year":"1979","unstructured":"Shoulson I, Fahn S (1979) Huntington disease: clinical care and evaluation. Neurology 29(1):1\u20133","journal-title":"Neurology"},{"key":"12771_CR6","doi-asserted-by":"crossref","unstructured":"Kieburtz K et al (1996) Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 11(2):136\u2013142","DOI":"10.1002\/mds.870110204"},{"key":"12771_CR7","unstructured":"The voice of the Patient: Huntington's Disease 18 May 2022]; Available from: https:\/\/www.fda.gov\/files\/about%20fda\/published\/The-Voice-of-the-Patient--Huntington%E2%80%99s-Disease.pdf."},{"issue":"6","key":"12771_CR8","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/fcp.12077","volume":"28","author":"L Salem","year":"2014","unstructured":"Salem L et al (2014) The most appropriate primary outcomes to design clinical trials on Huntington\u2019s disease: meta-analyses of cohort studies and randomized placebo-controlled trials. Fundam Clin Pharmacol 28(6):700\u2013710","journal-title":"Fundam Clin Pharmacol"},{"issue":"12","key":"12771_CR9","first-page":"1520","volume":"70","author":"ER Dorsey","year":"2013","unstructured":"Dorsey ER et al (2013) Natural history of Huntington disease. JAMA Neurol 70(12):1520\u20131530","journal-title":"JAMA Neurol"},{"issue":"2","key":"12771_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1212\/WNL.54.2.452","volume":"54","author":"K Marder","year":"2000","unstructured":"Marder K et al (2000) Rate of functional decline in Huntington\u2019s disease. Huntington Study Group. Neurology 54(2):452\u2013458","journal-title":"Neurology"},{"issue":"1","key":"12771_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3233\/JHD-220555","volume":"12","author":"JD Long","year":"2023","unstructured":"Long JD et al (2023) Applying the Huntington\u2019s disease integrated staging system (HD-ISS) to observational studies. J Huntington\u2019s Dis 12(1):57\u201369","journal-title":"J Huntington's Dis"},{"issue":"2","key":"12771_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mdc3.12388","volume":"4","author":"GB Landwehrmeyer","year":"2017","unstructured":"Landwehrmeyer GB et al (2017) Data Analytics from Enroll-HD, a Global Clinical Research Platform for Huntington\u2019s Disease. Mov Disord Clin Pract 4(2):212\u2013224","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"12771_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"DR Langbehn","year":"2004","unstructured":"Langbehn DR et al (2004) A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length. Clin Genet 65(4):267\u2013277","journal-title":"Clin Genet"},{"issue":"2","key":"12771_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153B","author":"DR Langbehn","year":"2010","unstructured":"Langbehn DR et al (2010) CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 153B(2):397\u2013408","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"12771_CR15","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2021","unstructured":"R Core Team (2021) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna"},{"issue":"43","key":"12771_CR16","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H et al (2019) Welcome to the Tidyverse. J Open Source Softw 4(43):1686. https:\/\/doi.org\/10.21105\/joss.01686","journal-title":"J Open Source Softw"},{"issue":"49","key":"12771_CR17","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.21105\/joss.02017","volume":"5","author":"J Brunson","year":"2020","unstructured":"Brunson J (2020) ggalluvial: layered grammar for alluvial plots. J Open Source Softw 5(49):2017. https:\/\/doi.org\/10.21105\/joss.02017","journal-title":"J Open Source Softw"},{"issue":"10","key":"12771_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1212\/WNL.31.10.1333","volume":"31","author":"I Shoulson","year":"1981","unstructured":"Shoulson I (1981) Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 31(10):1333\u20131335","journal-title":"Neurology"},{"issue":"2","key":"12771_CR19","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.psychres.2010.04.030","volume":"178","author":"LJ Beglinger","year":"2010","unstructured":"Beglinger LJ et al (2010) Earliest functional declines in Huntington disease. Psychiatry Res 178(2):414\u2013418","journal-title":"Psychiatry Res"},{"key":"12771_CR20","volume-title":"F25 The functional rating scale 2.0 (FuRST 2.0): from focus groups to focus-HD","author":"M Roch\u00e9","year":"2022","unstructured":"Roch\u00e9 M et al (2022) F25 The functional rating scale 2.0 (FuRST 2.0): from focus groups to focus-HD. BMJ Publishing Group Ltd"},{"issue":"12","key":"12771_CR21","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1002\/mds.28789","volume":"36","author":"EI McDonnell","year":"2021","unstructured":"McDonnell EI et al (2021) Age of onset of Huntington\u2019s disease in carriers of reduced penetrance alleles. Mov Disord 36(12):2958\u20132961","journal-title":"Mov Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12771-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12771-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12771-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T11:42:11Z","timestamp":1739619731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12771-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["12771"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12771-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"O.M. Dekker is Deputy Editor European Journal of Endocrinology. R.A.C. Roos is member of the DSMB uniQure CT-AMT 130, DSMB Enroll-HD. Susanne T. de Bot is a member of the HD Expert Advisory Panel for the PTC518 phase 3 program (PTC Therapeutics).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was conducted in compliance with the ethical standards outlined in the Declaration of Helsinki. All sites obtained and maintained local ethical approval. All participants provided informed consent prior to participation in the study, and their confidentiality and privacy were maintained throughout.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Standard Statement"}}],"article-number":"140"}}